Agilent Technologies Expands Informatics Portfolio with Electronic Notebook for Life Sciences, Chemical Analysis After Acquiring Kalabie from Klee Group

Kalabie ELN Highly Complementary to Agilent OpenLAB

SANTA CLARA, Calif.–Agilent Technologies Inc. (NYSE:A – News) today announced it has acquired the Klee Group’s Kalabie Electronic Laboratory Notebook (ELN). The focus for this product, which is Agilent’s first electronic notebook, will be on the pharmaceutical market and some chemical applications. Financial details of the acquisition were not disclosed.

Kalabie ELN is a highly configurable software solution for the R&D sector, used by leading pharmaceutical and dermo-cosmetic companies since 2004 to boost productivity and enhance collaboration of chemistry and biology scientists. A digital laboratory notebook, Kalabie ELN provides a foundation for knowledge and process management as well as intellectual property protection within laboratories. Kalabie ELN centralizes and secures all data from experimental work with a high level of traceability. Offering a rich package of features plus flexibility, Kalabie ELN can be deployed as a standard packaged solution or it can be configured to meet customers’ specific needs.

Agilent’s current portfolio of laboratory software includes OpenLAB — the operating system for the laboratory. Agilent plans to integrate the Kalabie ELN product into OpenLAB in the next six months to provide customers with the ability to manage computing resources in the laboratory with a complete solution.

“With the addition of Kalabie, Agilent can provide customers with a complete software solution and a single-vendor approach to their laboratory management needs,” said Bruce von Herrmann, vice president and general manager for Agilent’s Software and Informatics Division. “ELNs simplify knowledge and data integration. The combined capabilities of Kalabie ELN, OpenLAB and GeneSpring provide unique capabilities that enhance productivity.”

“Integrating into Agilent’s software and informatics portfolio is exciting for the Kalabie ELN team,” said Alain Meller, Kalabie director at the Klee Group. “This will immediately provide our customers the benefits of Agilent’s global reach and support capabilities, allowing for rapid deployment of ELN solutions across organizations and geographies. Moreover, with the combined capabilities that Agilent OpenLAB offers, we will speed up our ability to market and deliver high-value, global, integrated lab informatics solutions where the ELN is a key component.”

Prior to its acquisition by Agilent, Kalabie was a division of Klee Group, an information systems consulting firm founded in 1987. It is a private company based in France, Spain and Italy. All members of the Kalabie team have joined Agilent and will continue to be based in Paris and Montpellier, France. More information about Kalabie is available at

Agilent in Life Sciences and Chemical Analysis

Agilent’s Life Sciences and Chemical Analysis (LSCA) business is a world-leading provider of instruments, supplies, software and services to the life science and chemical analysis markets. It is a leading provider of microarray, microfluidic, liquid chromatography, gas chromatography, mass spectrometry and informatics-based solutions to pharmaceutical, biotech, academic, government and chemical organizations.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A – News) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.0 billion in fiscal year 2006. Information about Agilent is available on the Web at

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the Kalabie product and its enhancement of and integration into our product portfolio, expectations regarding the contribution Kalabie would make to Agilent’s ability to address customer demands, and the ability of Agilent to provide improved products, services and support to its customers as a result of this product acquisition. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, risks associated with the integration of the Kalabie product into Agilent’s business model and its product portfolio, changes in demand for Agilent’s products, and risks associated with the development generally of Agilent’s overall strategic objectives.

In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; ongoing competitive, pricing and gross margin pressures; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended April 30, 2007. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at


Agilent Corporate

Michele Drake, +1-408-345-8396 (Editorial)

[email protected]


Agilent LSCA

Stuart Matlow, +1-408-553-7191 (Editorial)

[email protected]



Rodney Gonsalves, +1-408-345-8948 (Investors)

[email protected]


Source: Agilent Technologies Inc.

< | >